The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta ‐analysis

Abstract The differential expression of soluble programmed death ligand 1 (sPD‐L1) has been found in some cancers; however, the correlation between sPD‐L1 expression and prognosis value in tumour is still unclear. Here, we conducted a meta‐analysis and systematic review to assess the prognostic value of sPD‐L1 in patients with cancer. Eligible studies were searched for in the databases including PubMed, Web of Science, ScienceDirect and Wiley Online Library database. The pooled hazard ratios (HRs) with a 95% confidence interval (95%CI) were calculated to assess the prognostic significance of sPD‐L1 in human cancer. Eight studies and 1102 patients with cancer were included in the final analysis, and the combined analysis indicated that a higher level of sPD‐L1 was associated with worse overall survival (OS) (HR = 1.60, 95%CI: 1.21–1.99). Furthermore, statistical significance was also observed in subgroup analysis stratified by the cancer type (haematological neoplasms or non‐haematological neoplasms), sample size (more or less than 100), cut‐off value of sPD‐L1 (more or less than 6.51 ng/ml) and ethnicity (Asian or European). The meta‐analysis indicates that circulating sPD‐L1 changes may serve as a useful biomarker for cancer prognosis, and higher level of sPD‐L1 may also be associated with poor outcomes in patients with cancer.
Source: Scandinavian Journal of Immunology - Category: Allergy & Immunology Authors: Tags: Review Source Type: research